Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subdose esketamine for postoperative anxiety and depression in breast cancer surgery
ChiCTR2400087464Phase 4Recruiting
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in breast cancer, major depressive disorder (MDD) and anxiety disorder comparing Esketamine subdose arm with Placebo (normal saline) arm (2 arms). Primary endpoints: PHQ-9 score and SAS score. Started Jul 2024; status: recruiting.
02
Drugs
esketamine
03
Conditions
breast cancermajor depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on ChiCTR2400087464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087464.